Eli Lilly said the SURPASS-3 and SURPASS-5 phase III clinical trials showed that the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide significantly reduced HbA1c and body weight in adults with type 2 diabetes — meeting both trials’ primary and key secondary endpoints.
In other trial success, the SKYLIGHT 1 and SKYLIGHT 2 phase III clinical trials also met all their primary endpoints with the investigational, oral, nonhormonal compound fezolinetant for moderate to severe vasomotor symptoms of menopause, Astellas announced.
Girls with overweight and obesity tended to have higher levels of certain hormones like follicle-stimulating hormone, inhibin B, and testosterone during puberty compared with normal weight girls. “In some girls with higher total body fat, higher testosterone levels were associated with irregular menstrual cycles, acne, and excess body hair,” added study author Natalie Shaw, MD, of the National Institute of Environmental Health Sciences, in a statement. (Journal of Clinical Endocrinology & Metabolism)
The U.S. Preventive Services Task Force is asking for comments through March 15 on its draft recommendation statement on screening for gestational diabetes mellitus.
USPSTF is also seeking comments on a draft research plan regarding menopausal hormone therapy for the primary prevention of chronic conditions in postmenopausal women, through March 17.
A Mendelian randomization study found that vitamin D levels did not impact type 1 diabetes development. (ScienceDaily)
In a 20-year follow-up study of adult trans men using testosterone, 11% experienced erythrocytosis, with the largest increases in hematocrit seen in the first year of hormone initiation. (Journal of Clinical Endocrinology & Metabolism)
A phase IIa clinical trial is in the works being led by Jennifer Miller, MD, of the University of Florida, to study an investigative psilocybin-based treatment for over-eating disorders, Tryp Therapeutics announced.